Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Giredestrant (GDC-9545) potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain. Giredestrant has anti-tumor activity. Giredestrant, a non-steroidal ER ligand, is an orally active and selective estrogen receptor (ER) antagonist.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 169.00 | |
2 mg | In stock | $ 213.00 | |
5 mg | In stock | $ 289.00 | |
10 mg | In stock | $ 463.00 | |
25 mg | In stock | $ 872.00 | |
50 mg | In stock | $ 1,390.00 | |
100 mg | In stock | $ 2,180.00 | |
200 mg | In stock | $ 2,970.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 332.00 |
Description | Giredestrant (GDC-9545) potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain. Giredestrant has anti-tumor activity. Giredestrant, a non-steroidal ER ligand, is an orally active and selective estrogen receptor (ER) antagonist. |
In vitro | The highly potent in vivo efficacy of Giredestrant likely arises due to the particular combination of high binding potency, full suppression of ER signaling, and an improved DMPK profile.Giredestrant (GDC-9545) is a novel ER antagonist and clinical candidate that combines desirable mechanistic and pre-clinical DMPK attributes. |
Synonyms | GDC-9545 |
Molecular Weight | 522.55 |
Formula | C27H31F5N4O |
CAS No. | 1953133-47-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (191.37 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Giredestrant 1953133-47-5 Endocrinology/Hormones Estrogen/progestogen Receptor Estrogen Receptor/ERR ligand conformational inhibit non-steroidal anti-tumor GDC9545 GDC-9545 Inhibitor orally change GDC 9545 inhibitor